The introduction of bortezomib has significantly improved the treatment landscape for multiple myeloma and mantle cell lymphoma. Studies have shown that bortezomib can lead to higher response rates and longer survival compared to traditional chemotherapy. It is often used in combination with other drugs to enhance its efficacy, providing a robust option for patients who have relapsed or are resistant to other treatments.
